share_log

Novo Integrated Sciences | 10-Q: Quarterly report

Novo Integrated Sciences | 10-Q: Quarterly report

Novo Integrated Sciences | 10-Q:季度報表
美股sec公告 ·  07/19 17:11
Moomoo AI 已提取核心訊息
Novo Integrated Sciences reported financial results for the quarter ended May 31, 2024, with revenues of $3,151,851, a slight decrease from $3,292,933 in the same period last year. The company's operating loss widened to $2,520,203 from $1,430,418 year-on-year, primarily due to increased operating expenses and a significant loss from the change in fair value of derivative liability. Net loss for the quarter was substantial at $13,741,903, compared to $1,497,330 in the previous year, largely impacted by the derivative liability and foreign currency exchange losses. For the nine-month period, revenues increased by 10% to $10,213,661, but the net loss also grew to $21,168,374 from $10,054,098. The company's financial performance was affected by various factors, including changes in product costs, higher operating costs, and increased interest expenses due to...Show More
Novo Integrated Sciences reported financial results for the quarter ended May 31, 2024, with revenues of $3,151,851, a slight decrease from $3,292,933 in the same period last year. The company's operating loss widened to $2,520,203 from $1,430,418 year-on-year, primarily due to increased operating expenses and a significant loss from the change in fair value of derivative liability. Net loss for the quarter was substantial at $13,741,903, compared to $1,497,330 in the previous year, largely impacted by the derivative liability and foreign currency exchange losses. For the nine-month period, revenues increased by 10% to $10,213,661, but the net loss also grew to $21,168,374 from $10,054,098. The company's financial performance was affected by various factors, including changes in product costs, higher operating costs, and increased interest expenses due to a higher average principal balance of convertible notes. Novo Integrated Sciences also highlighted business developments such as the launch of MiTelemed+, the expansion of its healthcare services, and the development of health and wellness products. Looking ahead, the company plans to continue focusing on its three primary pillars: service networks, interconnected technology, and health and wellness products, to drive future growth.
Novo Integrated Sciences報告了截至2024年5月31日的財務業績,收入爲3151851美元,略低於去年同期的3292933美元。由於營業費用增加和衍生負債公允價值變動造成的巨額虧損,公司的營業虧損從去年同期的1430418美元擴大至2520203美元。本季度淨虧損高達13741903美元,而去年同期僅爲1497330美元,主要受到衍生負債和貨幣兌換損失的影響。在爲期九個月的時間裏,收入增長了10%至10213661美元,但淨虧損也從10054098美元增加至21168374美元。公司的財務表現受到多種因素的影響,包括產品成本的變化、較高的營業成本以及可轉換票據平均本金餘額增加導致利息支出增加。Novo Integrated Sciences還強調了業務發展,例如推出MiTelemed+,擴大其醫療服務和開發健康和養生產品。展望未來,公司計劃繼續專注於其三個主要支柱——服務網絡、互連科技和健康和養生產品,以推動未來的增長。
Novo Integrated Sciences報告了截至2024年5月31日的財務業績,收入爲3151851美元,略低於去年同期的3292933美元。由於營業費用增加和衍生負債公允價值變動造成的巨額虧損,公司的營業虧損從去年同期的1430418美元擴大至2520203美元。本季度淨虧損高達13741903美元,而去年同期僅爲1497330美元,主要受到衍生負債和貨幣兌換損失的影響。在爲期九個月的時間裏,收入增長了10%至10213661美元,但淨虧損也從10054098美元增加至21168374美元。公司的財務表現受到多種因素的影響,包括產品成本的變化、較高的營業成本以及可轉換票據平均本金餘額增加導致利息支出增加。Novo Integrated Sciences還強調了業務發展,例如推出MiTelemed+,擴大其醫療服務和開發健康和養生產品。展望未來,公司計劃繼續專注於其三個主要支柱——服務網絡、互連科技和健康和養生產品,以推動未來的增長。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息